An interventional study of GIP-A and GIP(1-42) in Glucose Metabolism, sponsored by University Hospital, Gentofte, Copenhagen. Completed at 1 site in Denmark. Open to male participants aged 20 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-27.
Sponsored by University Hospital, Gentofte, Copenhagen · Not applicable, Interventional, and Basic science
Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion.
Aim: To evaluate the GIP receptor antagonizing effect of peptide-based competitive GIP receptor antagonist GIP-A (vs. saline (placebo)) in 10 healthy subjects during 1 hour hyperglycaemic clamps with and without concomitant iv infusion of GIP[1-42]. The intention is to establish GIP-A as a tool to eliminate glucose-dependent insulinotropic GIP signalling.
The study consists of four experimental days (A-D) with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A) GIP[1-42], B) GIP-A, C) GIP[1-42] + GIP-A, or D) saline (placebo).
University Hospital, Gentofte, Copenhagen is the lead sponsor of 154 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Infusion of saline
Other: Saline
Infusion of agonist, GIP(1-42)
Drug: GIP(1-42)
Infusion of GIP-A alone
Drug: GIP-A
Infusion of GIP-A and GIP(1-42)
Drug: GIP-A · Drug: GIP(1-42)
GIP receptor antagonist
GIP receptor agonist
Placebo
Insulin levels
Serum-insulin AUC (area under the curve for hyperglycemic clamp period)
Time frame: 65 minutes
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Gentofte, Copenhagen